ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · Real-Time Price · USD
9.00
-0.48 (-5.05%)
Nov 5, 2024, 1:19 PM EST - Market open

ORIC Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2017
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2017
Selling, General & Admin
27.3525.6125.0922.0113.425.73
Upgrade
Research & Development
97.7785.1761.6856.8635.9222.84
Upgrade
Operating Expenses
125.12110.7886.7778.8749.3428.57
Upgrade
Operating Income
-125.12-110.78-86.77-78.87-49.34-28.57
Upgrade
Interest & Investment Income
14.3410.082.650.140.311.4
Upgrade
Other Non Operating Income (Expenses)
---0.020.180.29
Upgrade
EBT Excluding Unusual Items
-110.78-100.7-84.12-78.72-48.86-26.88
Upgrade
Pretax Income
-110.78-100.7-89.12-78.72-73.7-26.88
Upgrade
Net Income
-110.78-100.7-89.12-78.72-73.7-26.88
Upgrade
Net Income to Common
-110.78-100.7-89.12-78.72-73.7-26.88
Upgrade
Shares Outstanding (Basic)
63514038222
Upgrade
Shares Outstanding (Diluted)
63514038222
Upgrade
Shares Change (YoY)
48.28%29.75%4.48%72.97%1055.26%9.53%
Upgrade
EPS (Basic)
-1.75-1.96-2.25-2.07-3.36-14.15
Upgrade
EPS (Diluted)
-1.75-1.96-2.25-2.07-3.36-14.15
Upgrade
Free Cash Flow
-100.41-86.54-77.22-60.48-45.94-24.3
Upgrade
Free Cash Flow Per Share
-1.59-1.68-1.95-1.59-2.09-12.79
Upgrade
EBITDA
-124.06-109.75-85.8-77.97-48.37-27.54
Upgrade
D&A For EBITDA
1.051.030.970.90.971.03
Upgrade
EBIT
-125.12-110.78-86.77-78.87-49.34-28.57
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.